Stocks and Investing Stocks and Investing
Wed, August 17, 2022
Tue, August 16, 2022

Salim Syed Maintained (ATRA) at Strong Buy with Decreased Target to $775 on, Aug 16th, 2022


Published on 2024-10-27 22:41:14 - WOPRAI, Salim Syed
  Print publication without navigation


Salim Syed of Mizuho, Maintained "Atara Biotherapeutics, Inc." (ATRA) at Strong Buy with Decreased Target from $975 to $775 on, Aug 16th, 2022.

Salim has made no other calls on ATRA in the last 4 months.



There are 6 other peers that have a rating on ATRA. Out of the 6 peers that are also analyzing ATRA, 2 agree with Salim's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Anupam Rama of "JP Morgan" Downgraded from Buy to Hold and Held Target at $250 on, Wednesday, July 13th, 2022
  • Benjamin Burnett of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $125 on, Wednesday, July 13th, 2022


These are the ratings of the 4 analyists that currently disagree with Salim


  • Tommie Reerink of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $75 on, Tuesday, August 9th, 2022
  • Yigal Nochomovitz of "Citigroup" Downgraded from Hold to Strong Sell and Held Target at $75 on, Wednesday, July 20th, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $100 on, Tuesday, May 24th, 2022
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $725 on, Monday, May 23rd, 2022
Contributing Sources